U.S. Pharmacist Weekly News Update
June 19, 2019

Large Trial Finds Proton
Pump Inhibitors Safe for
Long-Term Use

Pharmacists have reassuring news to share with patients using proton pump inhibitors over the long term: A large trial found no link between the drugs often prescribed to treat gastroesophageal reflux disease and a range of serious health issues, despite questions raised by population studies. Here are the details.


Early Study Suggests Immunotherapy Might Slow
Type 1 Diabetes Progression

The Holy Grail in type 1 diabetes is finding an agent that will prevent—or at least delay—the destruction of insulin-producing beta cells. Researchers appear to have moved a few steps closer to that, with a report that a type of immunotherapy delayed type 1 diabetes development in high-risk relatives of patients already diagnosed with the disease. Here is more information.

Concerns About GI Events Continue With Sodium Polystyrene Sulfonate
Sodium polystyrene sulfonate continues to be used to treat hyperkalemia, despite some past problems when the drug was combined with some other medications. Researchers warn, however, that users still have higher rates of hospitalization for gastrointestinal events. Find out how great that risk can be.

Older Women Face Increased CVD Risks With Extended Antibiotic Use
Pharmacists who refill longer term antibiotic prescriptions for older women might be especially interested in results of a new study: Researchers determined increased cardiovascular event risks in those patients. Find out which groups are affected and their risks.


Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App